Fulcrum Therapeutics, Inc. (FULC) intrinsic value & 10-year financials
Fulcrum Therapeutics, Inc. (FULC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue grew 73.5% a year to $0, with an average return on invested capital of -116.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.65
- Market cap
- $231.2K
- Revenue (FY2025)
- $0
- Revenue growth (9-yr CAGR)
- 73.5%
- ROIC (10-yr avg)
- -116.5%
- Free cash flow (FY2025)
- -$60.4M
FULC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$74.9M | -$1.18 | -$60.4M | — | -48.9% |
| FY2024 | $80.0M | -$9.7M | -$0.16 | -$2.5M | -27.4% | -10.7% |
| FY2023 | $2.8M | -$97.3M | -$1.59 | -$91.5M | -3945.2% | -49.5% |
| FY2022 | $6.3M | -$109.9M | -$2.44 | -$99.0M | -1774.9% | -62.6% |
| FY2021 | $19.2M | -$80.8M | -$2.29 | -$80.2M | -423.0% | -45.9% |
| FY2020 | $8.8M | -$70.8M | — | -$55.0M | -811.6% | -77.7% |
| FY2019 | — | -$82.7M | — | -$40.3M | — | -704.1% |
| FY2018 | — | -$32.6M | — | -$31.5M | — | 67.2% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Fulcrum Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Fulcrum Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -29.4% ROIC.
Fulcrum Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Fulcrum Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-39.19 per share.